

Review, National Institutes of Health, 6701 Rockledge Drive, Room 4210, MSC 7812, Bethesda, MD 20892, (301) 435-1221.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* July 9, 1999.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Hotel, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Sami A. Mayyasi, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5112, MSC 7852, Bethesda, MD 20892, (301) 435-1169.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* July 9, 1999.

*Time:* 3:30 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Alec S. Liacouras, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5154, MSC 7842, Bethesda, MD 20892, (301) 435-1740.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, ZRG-1 AARR-3 (02).

*Date:* July 10, 1999.

*Time:* 8:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Hotel, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Mohindar Poonian, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5222, MSC 7852, Bethesda, MD 20892, 301-435-1168, poonianm@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 28, 1999.

**Anna Snouffer,**

*Acting Committee Management Officer, NIH.*

[FR Doc. 99-16887 Filed 7-1-99; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Co-Exclusive License: Prodrug Forms of the Anti-Cancer Agent 9- $\beta$ -D-Arabinofuranosyl-2-Fluoroadenine as Therapeutics for the Treatment of Cancers and Leukemia

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide co-exclusive license to practice the invention embodied in U.S. Patent 4,357,324, issued November 2, 1982 and entitled "Prodrug Derivatives 9- $\beta$ -D-arabinofuranosyl-2-fluoroadenine", to Ash Stevens, Inc., having a place of business in Detroit, Michigan. The patent rights in these inventions have been assigned to the United States of America.

A co-exclusive license had been granted to Schering AG and its U.S. affiliate, Berlex Laboratories, Inc. in January 1984. PHS intends to grant one additional co-exclusive license to these patent rights.

The field of use may be limited to the development of therapeutics for the treatment of cancers and leukemia.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 31, 1999 will be considered.

**ADDRESSES:** Requests for a copy of the patent, inquiries, comments, and other materials relating to the contemplated license should be directed to: Girish C. Barua, PhD., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7057, ext. 263; Facsimile: (301) 402-0220; E-mail: BaruaG@od.nih.gov.

**SUPPLEMENTARY INFORMATION:** This invention involves the preparation of the 5'-formate and the 5'-phosphate derivatives of 9- $\beta$ -D-arabinofuranosyl-2-fluoroadenine as prodrug forms of the anti-cancer agent 9- $\beta$ -D-arabinofuranosyl-2-fluoroadenine, known as F-ara-A. These derivatives are quite water soluble whereas F-ara-A itself is sparingly soluble in water or in any organic solvents. Delivery of these prodrug forms to mice with L1210

leukemia results in the formation of higher levels of the triphosphate of F-ara-A, the active form of the drug, in the target L1210 leukemia cells. These prodrug forms are much more active chemotherapeutically than 9- $\beta$ -D-arabinofuranosyl, known as ara-A, and equivalent in activity to the combination of ara-A and 2-deoxycytosine, known as 2'-dCF, an effective in vivo inhibitor of adenosine deaminase, a ubiquitous enzyme that destroys ara-A in vivo.

The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: June 25, 1999.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 99-16895 Filed 7-1-99; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4432-N-26]

### Federal Property Suitable as Facilities To Assist the Homeless

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Notice.

**SUMMARY:** This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

**EFFECTIVE DATE:** July 2, 1999.

**FOR FURTHER INFORMATION CONTACT:**

Mark Johnston, Department of Housing and Urban Development, Room 7256, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708-1226; TTY number for the hearing- and speech-

impaired (202) 708-2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

**SUPPLEMENTARY INFORMATION:** In accordance with the December 12, 1988 court order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: June 24, 1999.

**Fred Karnas, Jr.,**

*Deputy Assistant Secretary for Economic Development.*

[FR Doc. 99-16585 Filed 7-1-99; 8:45 am]

BILLING CODE 4210-29-M

## DEPARTMENT OF THE INTERIOR

### **Office of the Assistant Secretary for Water and Science; Notice of Intent To Contract for Hydroelectric Power Development at the Jordan Aqueduct, Reach 4, Flow Control Structure (Jordan Aqueduct) and at Jordanelle Dam, Features of the Central Utah Project (CUP), Utah**

**AGENCY:** Office of the Assistant Secretary for Water and Science, Department of the Interior.

**ACTION:** Notice of intent to accept proposals, select one or more lessees, and contract for hydroelectric power development at Jordanelle Dam and Jordan Aqueduct.

**SUMMARY:** Current Federal policy encourages non-Federal development of electrical power resource potential on Federal water resource projects. The Department of the Interior (Interior), in consultation with the Department of Energy, Western Area Power Administration (Western), will consider proposals for non-Federal development of hydroelectric power at Jordanelle Dam and Jordan Aqueduct of the CUP, Utah. Interior is considering such hydroelectric power development under a lease of power privilege. No Federal funds will be available for such hydroelectric power development. Western would have the first opportunity to purchase and/or market the power that would be generated by such development under a lease of power privilege. The CUP is a Federal

Bureau of Reclamation (Reclamation) project. This notice presents background information, proposal content guidelines, information concerning selection of one or more non-Federal entities to develop hydroelectric power at Jordanelle Dam and on the Jordan Aqueduct, and power purchasing and/or marketing considerations. Interested entities are invited to submit on one or both of these projects. That is, Interior will consider proposals by interested entities on only Jordanelle Dam, on only Jordan Aqueduct, or on both projects.

**DATES:** A written proposal and seven copies must be submitted on or before 5:00 p.m. (MST), on January 7, 2000, to: Mr. Ronald Johnston, Program Director, Central Utah Project Completion Act, Department of the Interior, 302 East 1860 South, Provo UT 84606-7317, Telephone: (801) 379-1103.

A proposal will be considered timely only if it is received in the office of the Program Director by or before 5:00 p.m. on the designated date. Interested entities are cautioned that delayed delivery to this office due to failures or misunderstandings of the entity and/or of mail, overnight, or courier services will not excuse lateness and, accordingly, are advised to provide sufficient time for delivery. Late proposals will not be considered.

A copy of the proposal should also be sent at or about the time it is due at Interior to: Mr. Dave Sabo, CRSP Manager, Western Area Power Administration, 257 East 200 South, Suite 475, Salt Lake City UT 84111-0606.

**FOR FURTHER INFORMATION:** Contact Technical data may be obtained at the address and telephone number set forth below:

Mr. Ronald Johnston, Program Director, Central Utah Project Completion Act, Department of the Interior, 302 East 1860 South, Provo UT 84606-7317, Telephone: (801) 379-1103

Interior will be available to meet with interested entities only upon written request to the Program Director at the above address. Interior reserves the right to schedule a single meeting and/or visit to address at once the questions of all entities that have submitted questions or requested site visits.

Information related to Western's purchasing and/or marketing the power may be obtained at the address and telephone number set forth below:

Mr. Dave Sabo, CRSP Manager, Western Area Power Administration, 257 East 200 South, Suite 475, Salt Lake City UT 84111-0606, Telephone: (801) 524-6372

Information related to the operation and maintenance of Jordanelle Dam and Jordan Aqueduct may be obtained at the address and telephone number set forth below:

Mr. Rich Tullis, Central Utah Water Conservancy District, 355 West University Parkway, Orem UT 84058-7303, (801) 226-7122

### **Background Information**

The CUP, Bonneville Unit, located in northern Utah, was authorized for construction, including hydroelectric power, by the Colorado River Storage Project (CRSP) Act of April 11, 1956 (ch. 203, 70 Stat. 105) (CRSP Act). The United States constructed Jordanelle Dam and Jordan Aqueduct under the CRSP Act. The Central Utah Project Completion Act (CUPCA), comprised of Titles II-VI of the Act of October 30, 1992 (106 Stat. 4600, Pub. L. 102-575) authorized the construction of other features of the Bonneville Unit. Section 208 of the CUPCA provides that power generation facilities associated with the CUP be developed and operated in accordance with the CRSP Act, which explicitly embodies all Reclamation law except as otherwise provided in the CRSP Act. The Central Utah Water Conservancy District (District), under its contracts with the United States, has certain operation, maintenance, replacement, and repayment responsibilities and obligations concerning the Bonneville Unit, which includes such responsibility for Jordanelle Dam and Jordan Aqueduct. The District has contracted with the Salt Lake County Water Conservancy District for the operation and maintenance of Jordan Aqueduct.

Interior, in consultation with Western, is considering hydroelectric power development at Jordanelle Dam and the Jordan Aqueduct through one or more leases of power privilege. A lease of power privilege is an alternative to Federal hydroelectric power development. A lease of power privilege grants to a non-Federal entity the right to utilize, consistent with CUP purposes, water power head or storage at and/or operationally in conjunction with the CUP, for non-Federal electric power generation and sale by the entity. Leases of power privilege have terms not to exceed 40 years. The general authority for lease of power privilege under Reclamation law includes, among others, the Town Sites and Power Development Act of 1906 (43 U.S.C. §522) and the Reclamation Project Act of 1939 (43 U.S.C. 485h(c)) (1939 Act). Interior will be the lead Federal agency for ensuring compliance with the